Updates are available Correction dated 2024-07-01
Click to view Correction: https://doi.org/10.1038/s41591-024-03126-z
-
Authors
Volinsky-Fremond, Sarah https://orcid.org/0000-0002-8195-5735
Horeweg, Nanda https://orcid.org/0000-0002-8581-4753
Andani, Sonali
Barkey Wolf, Jurriaan https://orcid.org/0000-0002-7811-0280
Lafarge, Maxime W.
de Kroon, Cor D.
Ørtoft, Gitte
Høgdall, Estrid
Dijkstra, Jouke https://orcid.org/0000-0002-8666-3731
Jobsen, Jan J.
Lutgens, Ludy C. H. W.
Powell, Melanie E.
Mileshkin, Linda R. https://orcid.org/0000-0001-6826-6014
Mackay, Helen
Leary, Alexandra
Katsaros, Dionyssios
Nijman, Hans W.
de Boer, Stephanie M.
Nout, Remi A.
de Bruyn, Marco https://orcid.org/0000-0001-9819-9131
Church, David
Smit, Vincent T. H. B. M.
Creutzberg, Carien L.
Koelzer, Viktor H. https://orcid.org/0000-0001-9206-4885
Bosse, Tjalling https://orcid.org/0000-0002-6881-8437
- License Information
-
More Information
Article History
Received: 27 November 2023
Accepted: 11 April 2024
First Online: 24 May 2024
Change Date: 1 July 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-024-03126-z
Competing interests
: S.V.-F., N.H., V.H.K. and T.B. are co-inventors on the patent application no. 23315438.4 related to the present study. N.H. declares having received research grants from the DCS and Varian (paid to the institution) unrelated to the present study. C.D.d.K. declares KWF and ZonMW grants unrelated to the project. A.L. received funded research unrelated to the present study from AZ, Clovis, GSK, MSD, Ability, Zentalis, Agenus, Lovance, Sanofi, Roche, OSEimmuno and BMS, is an advisory board member or consultant for AZ, Clovis, GSK, MSD, Merck Serono, Ability, Zentalis, Agenus and Blueprint, and received honoraria and compensation for expenses from AZ, Clovis and GSK. R.A.N. declared research grants unrelated to the present study to the institution from Elekta, Varian, Accuray and Sensius, and is an advisory board member of MSD. M.d.B. received grants from the DCS, the European Research Council, Health Holland, Mendus, BioNovion, Aduro Biotech, Vicinivax, Genmab and IMMIOS (all paid to the institute) unrelated to the present study, received nonfinancial support from BioNTech, Surflay Nanotec and Merck Sharp & Dohme, and is a stock option holder in Sairopa. D.C. is on an advisory board of MSD, received research funding unrelated to the project of HalioDx and Veracyte (to TransSCOT consortium), is a spouse of an Amgen employee, is affiliated to the Wellcome Centre for Human Genetics and National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre (BRC), and received funding from Oxford NIHR Comprehensive BRC and a Cancer Research UK (CRUK) Advanced Clinician Scientist Fellowship (C26642/A27963). C.L.C. received grants from the DCS for the PORTEC-1,-2,-3,-4a, RAINBO trials and research grant for translational work on PORTEC unrelated to the present study, and has leadership roles in and is chair of GCIG Endometrial Cancer Committee. V.H.K. declared being an invited speaker for Sharing Progress in Cancer Care and Indica Labs, is on the advisory board of Takeda and sponsored research agreements with Roche and IAG, all unrelated to the present study. T.B. received grants unrelated to this work by the DCS. The other authors declare no competing interests.
